Immuron SARS-CoV-2 Research Agreement with Monash University
December 15 2020 - 6:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercialising
oral immunotherapeutics for the prevention and treatment of gut
pathogens, today is pleased to provide shareholders and the market
with an update on progress made for the further development of the
anti-viral activity of IMM-124E. The company has been actively
engaging with local, national, and international research
collaborators to advance this work and assist in the further
characterization of the neutralization activity of SARS-CoV-2
observed with Immuron’s commercial hyper-immune colostrum used to
manufacture the company’s flag ship commercially available and
over-the-counter gastrointestinal and digestive health immune
supplements Travelan® and Protectyn®.
The company has recently executed a new Research
Agreement with Monash University to develop new assays to evaluate
the efficacy of IMM-124E, the active pharmaceutical ingredient used
to manufacture Travelan® and Protectyn® to further our
understanding of the inhibitory substance/s in our commercial
products.
The research team will be led by Dr Melanie
Hutton and Professor Dena Lyras, Deputy Director, Biomedicine
Discovery Institute and Deputy Head, Department of Microbiology who
will utilize two new recombinant reagents, the SARS-CoV-2 Spike
protein, a receptor binding domain protein as well as an antibody
positive human serum sample obtained from Melbourne’s Peter Doherty
Institute for Infection and Immunity.
“We have been very fortunate to obtain access to
the SARS-CoV-2 recombinant proteins developed at the Peter Doherty
Institute for Infection and Immunity,” said Professor Lyras. “These
reagents will be used to initiate the research work and to develop
a suitable assay for evaluating the inhibitory efficacy of
IMM-124E. Furthermore, specific immune components will be purified
from IMM-124E and will be used to evaluate their ability to inhibit
the binding of an antibody positive human serum sample to specific
COVID-19 proteins, such as the spike protein which is crucial for
cell entry,” said Dr Hutton.
This release has been authorised by the
directors of Immuron Limited.
COMPANY
CONTACT:Dr Jerry
Kanellos, Ph.D.Chief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com |
|
|
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024